Cited by 240Immunotherapy and Immune ResponsesRNA Interference and Gene DeliverySARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

Mechanism of action of mRNA-based vaccines

Iavarone, Carlo, O’hagan, Derek T., Yu, Dong, Delahaye, Nicolas F., Ulmer, Jeffrey B.·2017·Expert Review of Vaccines

DOI 10.1080/14760584.2017.1355245

Open this paper in CoChat — free account

Abstract

INTRODUCTION: The present review summarizes the growing body of work defining the mechanisms of action of this exciting new vaccine technology that should allow rational approaches in the design of next generation mRNA vaccines. Areas covered: Bio-distribution of mRNA, localization of antigen production, role of the innate immunity, priming of the adaptive immune response, route of administration and effects of mRNA delivery systems. Expert commentary: In the last few years, the development of RNA vaccines had a fast growth, the rising number of proof will enable rational approaches to improving the effectiveness and safety of this modern class of medicine.

Integrity signals

Registry

Crossref · 10.1080/14760584.2017.1355245

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 2×
“Wolff [2] demonstrated that uptake and expression of exogenous RNA can be achieved without a delivery system.”
Background
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Self-citation
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 1×
“Interaction among PRRs and PAMPs triggers the inflammatory response, the link between the innate immunity and the adaptive immunity [43].”
Background
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, É., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,831
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Genetic immunization is a simple method for eliciting an immune response
Tang, D.-C. C., DeVit, M. J., & Johnston, S. A. (1992) · Nature · doi:10.1038/356152a0 · Cited by 1,504
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells
Bedoui, S., Whitney, P. G., Waithman, J. C., Eidsmo, L., Wakim, L. M., Caminschi, I., Allan, R. S., Wojtasiak, M., Shortman, K., Carbone, F., et al. (2009) · Nature Immunology · doi:10.1038/ni.1724 · Cited by 707
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · cited 1×
“mediates and later positive-sense genomic and subgenomic (+)RNAs [14,15].”
BackgroundSelf-citation
Influenza Virus Aerosols in Human Exhaled Breath: Particle Size, Culturability, and Effect of Surgical Masks
Milton, D. K., Fabian, M. P., Cowling, B. J., Grantham, M. L., & McDevitt, J. J. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003205 · Cited by 669
Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
Simonsen, L., Reichert, T. A., Viboud, C. G., Blackwelder, W. C., Taylor, R. J., & Miller, M. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 541
Immunopathogenesis of coronavirus infections: implications for SARS
Dandekar, A. A., & Perlman, S. M. (2005) · Nature reviews. Immunology · doi:10.1038/nri1732 · Cited by 503
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473
A cluster randomised trial of cloth masks compared with medical masks in healthcare workers
MacIntyre, C. R., Seale, H., Dung, T. C., Hien, N. T., Nga, P. T., Chughtai, A. A., Rahman, B., Dwyer, D. E., & Wang, Q. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006577 · Cited by 471
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages
Sarén, P., Welgus, H. G., & Kovanen, P. T. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.9.4159 · Cited by 407
Engineering Nano‐ and Microparticles to Tune Immunity
Moon, J. J., Huang, B., & Irvine, D. J. (2012) · Advanced Materials · doi:10.1002/adma.201200446 · Cited by 406
Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN
van Gisbergen, K. P. J. M., Sánchez‐Hernández, M., Geijtenbeek, T. B. H., & van Kooyk, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041276 · Cited by 401
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a00068 · Cited by 378
Post-transcriptional regulation of gene expression in innate immunity
Carpenter, S. B., Ricci, E. P., Mercier, B. C., Moore, M. J., & Fitzgerald, K. A. (2014) · Nature reviews. Immunology · doi:10.1038/nri3682 · Cited by 373
Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
Senti, G., Prinz Vavricka, B. M., Erdmann, I., Diaz, M. I., Markus, R., McCormack, S. J., Simard, J. J., Wüthrich, B., Crameri, R., Graf, N., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803725105 · Cited by 364
Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets
Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338
Self-citation
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., & Kallen, K.-J. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f7dbe8 · Cited by 335 · cited 1×
“Cancer BioNTech Melanoma Complete NCT01684241 nr [36] BioNTech, Sanofi Melanoma Phase I NCT02410733 Assessing safety and tolerability [26] Curevac Prostate cancer Complete NCT00831467 Failed to meet primary end point of improving overall survival [37] Curevac NSCLC Phase I NCT01915524 Improved survival [19] TübingenUn…”
Background
Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis
Smith, J. D., MacDougall, C. C., Johnstone, J., Copes, R. A., Schwartz, B., & Garber, G. E. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.150835 · Cited by 328
Antibody-Dependent Enhancement of Virus Infection and Disease
Cancel-Tirado, S. M., & Yoon, K. J. (2003) · Viral Immunology · doi:10.1089/088282403763635465 · Cited by 316
Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309
Survival of airborne influenza virus: Effects of propagating host, relative humidity, and composition of spray fluids
Schaffer, F. L., Soergel, M. E., & Straube, D. C. (1976) · Archives of Virology · doi:10.1007/bf01317930 · Cited by 302
Effectiveness of masks and respirators against respiratory infections in healthcare workers: a systematic review and meta-analysis
Offeddu, V., Yung, C. F., Low, M. S. F., & Tam, C. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix681 · Cited by 297
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 289
An initial investigation of the association between the SARS outbreak and weather: with the view of the environmental temperature and its variation
Tan, J., Mu, L., Huang, J., Yu, S., Chen, B., & Yin, J. (2005) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2004.020180 · Cited by 288
In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles
Su, X., Fricke, J., Kavanagh, D. G., & Irvine, D. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100390w · Cited by 287
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer · doi:10.1186/s40425-015-0068-y · Cited by 287
Face masks to prevent transmission of influenza virus: a systematic review
Cowling, B. J., Zhou, Y., Ip, D., Leung, G. M., & Aiello, A. E. (2010) · Epidemiology and Infection · doi:10.1017/s0950268809991658 · Cited by 287
Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization
Vennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M. J. M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 276
TLR signaling in B-cell development and activation
Hua, Z., & Hou, B. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.61 · Cited by 267
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ce501 · Cited by 261 · cited 1×
“Cancer BioNTech Melanoma Complete NCT01684241 nr [36] BioNTech, Sanofi Melanoma Phase I NCT02410733 Assessing safety and tolerability [26] Curevac Prostate cancer Complete NCT00831467 Failed to meet primary end point of improving overall survival [37] Curevac NSCLC Phase I NCT01915524 Improved survival [19] TübingenUn…”
Background
Blocking Monoclonal Antibodies Specific for Mouse IFN- α / β Receptor Subunit 1 (IFNAR-1) from Mice Immunized by In Vivo Hydrodynamic Transfection
Sheehan, K. C. F., Lai, K. S., Dunn, G. P., Bruce, A. T., Diamond, M. S., Heutel, J. D., Dungo-Arthur, C., Carrero, J. A., White, J. M., Hertzog, P. J., et al. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.804 · Cited by 260
Toll‐like receptors – sentries in the B‐cell response
Bekeredjian-Ding, I., & Jego, G. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03173.x · Cited by 249
Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines
Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248
Minimum Infective Dose of the Major Human Respiratory and Enteric Viruses Transmitted Through Food and the Environment
Yezli, S., & Otter, J. A. (2011) · Food and Environmental Virology · doi:10.1007/s12560-011-9056-7 · Cited by 241
mRNA transcript therapy
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
Rittig, S. M., Haentschel, M., Weimer, K. J., Heine, A., Muller, M. R., Brugger, W., Horger, M. S., Maksimovic, O., Stenzl, A., Hoerr, I., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.289 · Cited by 226
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo
Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226
A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223
Cationic lipids activate intracellular signaling pathways
Lonez, C., Vandenbranden, M., & Ruysschaert, J.-M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.009 · Cited by 221
Modified mRNA Vaccines Protect against Zika Virus Infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.016 · Cited by 221
Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers
Bernstein, D. I., Reap, E. A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R. A., Hoeper, A., Morris, J., Negri, S., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.135 · Cited by 212
An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs
Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212 · cited 2×
“Infectious disease Curevac Rabies Phase I NCT02238756 Assessing safety and tolerability [35] Moderna Flu Phase I NCT03076385 Acceptable tolerability, protective immunity [42] Moderna Zika Phase II NCT03014089 Assessing safety, tolerability, and immunogenicity [24]”
Background
Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent
Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation
Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C. G., Türeci, Ö., & Şahin, U. (2011) · Gene Therapy · doi:10.1038/gt.2011.17 · Cited by 192
Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
Edwards, D. K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., & Wittman, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1111-6 · Cited by 186
Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA
Bonehill, A., Tuyaerts, S., Nuffel, A. M. T. V., Heirman, C., Bos, T. J., Fostier, K., Neyns, B., & Thielemans, K. (2008) · Molecular Therapy · doi:10.1038/mt.2008.77 · Cited by 185
Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion
Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J., Davis, D., Ulmer, J. B., Brito, L. A., Cu, Y., Banerjee, K., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu522 · Cited by 181
Self-citation
A Viral RNA Structural Element Alters Host Recognition of Nonself RNA
Hyde, J., Gardner, C. L., Kimura, T., White, J. P., Gai, L., Trobaugh, D. W., Huang, C., Tonelli, M., Paessler, S., Takeda, K., et al. (2014) · Science · doi:10.1126/science.1248465 · Cited by 179
mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes
Mockey, M., Bourseau, E., Voshavar, C., Chaudhuri, A., Lafosse, S., Cam, É. L., Quesniaux, V. F. J., Ryffel, B., Pichon, C., & Midoux, P. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701072 · Cited by 167
Infectious Cell Entry Mechanism of Influenza Virus
Yoshimura, A., Kuroda, K., Kawasaki, K., Yamashina, S., Maeda, T., & Ohnishi, S. (1982) · Journal of Virology · doi:10.1128/jvi.43.1.284-293.1982 · Cited by 164
Recent Developments in Nucleic Acid Delivery with Polyethylenimines
Neuberg, P., & Kichler, A. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00009-2 · Cited by 163
Alphavirus Infection: Host Cell Shut-Off and Inhibition of Antiviral Responses
Fros, J. J., & Pijlman, G. P. (2016) · Viruses · doi:10.3390/v8060166 · Cited by 158
Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin
Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154
Self-citation
Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway
Lorenz, C., Fotin‐Mleczek, M., Roth, G. D., Becker, C., Dam, T. C., Verdurmen, W. P. R., Brock, R. E., Probst, J., & Schlake, T. (2011) · RNA Biology · doi:10.4161/rna.8.4.15394 · Cited by 152
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
Sebastian, M., Papachristofilou, A., Weiß, C., Früh, M., Cathomas, R. L., Hilbe, W., Wehler, T., Rippin, G., Koch, S. D., Scheel, B., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-748 · Cited by 143
Self-replicating alphavirus RNA vaccines
Ljungberg, K., & Liljeström, P. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.965690 · Cited by 141
Challenges and advances towards the rational design of mRNA vaccines
Pollard, C., Koker, S. D., Saelens, X., Vanham, G. L., & Grooten, J. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.002 · Cited by 138
Immunostimulating capacities of stabilized RNA molecules
Scheel, B., Braedel, S., Probst, J., Carralot, J., Wagner, H., Schild, H., Jung, G., Rammensee, H., & Pascolo, S. (2004) · European Journal of Immunology · doi:10.1002/eji.200324198 · Cited by 138
Staufen1 senses overall transcript secondary structure to regulate translation
Ricci, E. P., Küçükural, A., Cenik, C., Mercier, B. C., Singh, G., Heyer, E. E., Ashar-Patel, A., Peng, L., & Moore, M. J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2739 · Cited by 130
Epidemiological and clinical features of human coronavirus infections among different subsets of patients
Cabeça, T. K., Granato, C. F. H., & Bellei, N. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12101 · Cited by 130
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells
Lint, S. V., Renmans, D., Broos, K., Goethals, L., Maenhout, S. K., Benteyn, D., Goyvaerts, C., Four, S. D., der Jeught, K. V., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130
Nucleoside modified mRNA vaccines for infectious diseases
Pardi, N., & Weissman, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_6 · Cited by 129
Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge
Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J. B., Gregorio, E. D., Geall, A. J., Brazzoli, M., & Bertholet, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161193 · Cited by 127
Self-citation
Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses
De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122
Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon
Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121
Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy
Martínez-Gómez, J. M., Johansen, P., Erdmann, I., Senti, G., Crameri, R., & Kündig, T. M. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000210381 · Cited by 117
Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
Youn, H., & Chung, J.-K. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1057563 · Cited by 114
ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells
Duewell, P., Kisser, U., Heckelsmiller, K., Hoves, S., Stoitzner, P., Koernig, S., Morelli, A. B., Clausen, B. E., Dauer, M., Eigler, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004114 · Cited by 112
Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli
Jefford, M., Schnurr, M. M., Toy, T., Masterman, K., Shin, A., Beecroft, T., Tai, T. Y., Shortman, K., Shackleton, M. J., Davis, I. D., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3854 · Cited by 110
Uses of granulocyte-macrophage colony-stimulating factor in vaccine development
Warren, T. L., & Weiner, G. J. (2000) · Current Opinion in Hematology · doi:10.1097/00062752-200005000-00007 · Cited by 110
Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 110
Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA
Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I., Rammensee, H., Weller, M., & Pascolo, S. (2006) · European Journal of Immunology · doi:10.1002/eji.200635910 · Cited by 108
The 5′ and 3′ ends of alphavirus RNAs – Non-coding is not non-functional
Hyde, J., Chen, R., Trobaugh, D. W., Diamond, M., Weaver, S. C., Klimstra, W. B., & Wilusz, J. (2015) · Virus Research · doi:10.1016/j.virusres.2015.01.016 · Cited by 105
Effect of pH and temperature on the infectivity of human coronavirus 229E
Lamarre, A., & Talbot, P. J. (1989) · Canadian Journal of Microbiology · doi:10.1139/m89-160 · Cited by 105
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2605 · Cited by 103
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
Kowalczyk, A., Doener, F., Zanzinger, K., Noth, J., Baumhof, P., Fotin-Mleczek, M., & Heidenreich, R. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.046 · Cited by 101
The enhancement of virus infectivity by antibody
Hawkes, R. A., & Lafferty, K. J. (1967) · Virology · doi:10.1016/0042-6822(67)90144-4 · Cited by 99
Venezuelan Equine Encephalitis Virus Disrupts STAT1 Signaling by Distinct Mechanisms Independent of Host Shutoff
Simmons, J. D., White, L., Morrison, T. E., Montgomery, S. A., Whitmore, A. C., Johnston, R. E., & Heise, M. T. (2009) · Journal of Virology · doi:10.1128/jvi.01041-09 · Cited by 99
Transient Pretreatment With Glucocorticoid Ablates Innate Toxicity of Systemically Delivered Adenoviral Vectors Without Reducing Efficacy
Seregin, S. S., Appledorn, D. M., McBride, A. J., Schuldt, N. J., Aldhamen, Y. A., Voss, T. T., Wei, J.-P., Bujold, M., Nance, W., Godbehere, S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.297 · Cited by 97
The ReNAissanCe of mRNA-based cancer therapy
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95
Regulation and dysregulation of 3′UTR-mediated translational control
Jia, J., Yao, P., Arif, A., & Fox, P. L. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.004 · Cited by 92
A Cell-Based, High-Throughput Screen for Small Molecule Regulators of Hepatitis C Virus Replication
Kim, S. S., Peng, L. F., Lin, W., Choe, W. H., Sakamoto, N., Schreiber, S. L., & Chung, R. T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.10.032 · Cited by 91
Alphavirus-Based Vaccines
Lundstrom, K. H. (2014) · Viruses · doi:10.3390/v6062392 · Cited by 91
Recent innovations in mRNA vaccines
Ulmer, J. B., & Geall, A. J. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.008 · Cited by 91
Self-citation
Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice
Selmi, A., Vascotto, F., Kautz‐Neu, K., Türeci, Ö., Şahin, U., von Stebut, E., Diken, M., & Kreiter, S. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1869-7 · Cited by 90
CD 8 T‐cell priming upon mRNA vaccination is restricted to bone‐marrow‐derived antigen‐presenting cells and may involve antigen transfer from myocytes
Lazzaro, S., Giovani, C., Mangiavacchi, S., Magini, D., Maione, D., Baudner, B. C., Geall, A. J., Gregorio, E. D., D’Oro, U., & Buonsanti, C. (2015) · Immunology · doi:10.1111/imm.12505 · Cited by 89
Characterization of the ribonuclease activity on the skin surface
Probst, J., Brechtel, S., Scheel, B., Hoerr, I., Jung, G., Rammensee, H.-G., & Pascolo, S. (2006) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-4-4 · Cited by 84
A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
Heidenreich, R., Jasny, E., Kowalczyk, A., Lutz, J., Probst, J., Baumhof, P., Scheel, B., Voss, S., Kallen, K., & Fotin‐Mleczek, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29402 · Cited by 80
Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice
Wen, Y., Monroe, J. E., Linton, C. E., Archer, J. F., Beard, C. W., Barnett, S. W., Palladino, G., Mason, P. W., Carfı́, A., & Lilja, A. E. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.05.004 · Cited by 80
Potential Therapeutic Applications of Rna Cap Analogs
Ziemniak, M., Strenkowska, M., Kowalska, J., & Jemielity, J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.96 · Cited by 76
Use of surgical face masks to reduce the incidence of the common cold among health care workers in Japan: a randomized controlled trial
Jacobs, J. L., Ohde, S., Takahashi, O., Tokuda, Y., Omata, F., & Fukui, T. (2009) · American Journal of Infection Control · doi:10.1016/j.ajic.2008.11.002 · Cited by 74
Ribosomal binding to the internal ribosomal entry site of classical swine fever virus
KOLUPAEVA, V. G., Pestova, T. V., & Hellen, C. U. T. (2000) · RNA · doi:10.1017/s1355838200000662 · Cited by 72
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy
Rittig, S. M., Haentschel, M., Weimer, K. J., Heine, A., Müller, M., Brugger, W., Horger, M., Maksimovic, O., Stenzl, A., Hoerr, I., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108511 · Cited by 67
Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
Avogadri, F., Merghoub, T., Maughan, M. F., Hirschhorn-Cymerman, D., Morris, J., Ritter, E., Olmsted, R. A., Houghton, A. N., & Wolchok, J. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012670 · Cited by 66
mRNA
Lint, S. V., Heirman, C., Thielemans, K., & Breckpot, K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22661 · Cited by 59
Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs
Kim, D. Y., Atasheva, S., McAuley, A. J., Plante, J. A., Frolova, E. I., Beasley, D. W. C., & Frolov, I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408677111 · Cited by 57
Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein
Cruz, C. C., Suthar, M. S., Montgomery, S. A., Shabman, R. S., Simmons, J. D., Johnston, R. E., Morrison, T. E., & Heise, M. T. (2010) · Virology · doi:10.1016/j.virol.2009.12.031 · Cited by 54
Introduction to RNA Vaccines
Kramps, T., & Elbers, K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_1 · Cited by 53
Duration of Antigen Expression In Vivo following DNA Immunization Modifies the Magnitude, Contraction, and Secondary Responses of CD8+ T Lymphocytes
Hovav, A., Panas, M. W., Rahman, S., Sircar, P., Gillard, G. O., Cayabyab, M. J., & Letvin, N. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6725 · Cited by 48
Intralymphatic immunotherapy
Senti, G., & Kündig, T. M. (2015) · World Allergy Organization Journal · doi:10.1186/s40413-014-0047-7 · Cited by 47
Control of alphavirus-based gene expression using engineered riboswitches
Bell, C. L., Yu, D. L., Smolke, C. D., Geall, A. J., Beard, C. W., & Mason, P. W. (2015) · Virology · doi:10.1016/j.virol.2015.04.023 · Cited by 44
Self-citation
A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates
Pyankov, O. V., Боднев, С. А., Pyankova, O. G., Solodky, V. V., Pyankov, S. A., Setoh, Y. X., Volchkova, V. A., Suhrbier, A., Volchkov, V. E., Agafonov, A. P., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv019 · Cited by 44
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Vormehr, M., Schrörs, B., Boegel, S., Löwer, M., Türeci, Ö., & Şahin, U. (2015) · Journal of Immunology Research · doi:10.1155/2015/595363 · Cited by 44
The 'anti-hype' vaccine
DeFrancesco, L. (2017) · Nature Biotechnology · doi:10.1038/nbt.3812 · Cited by 40
Kinetic and Phenotypic Analysis of CD8+ T Cell Responses after Priming with Alphavirus Replicons and Homologous or Heterologous Booster Immunizations
Knudsen, M., Ljungberg, K., Kakoulidou, M., Kostic, L., Hallengärd, D., García-Arriaza, J., Merits, A., Esteban, M., & Liljeström, P. (2014) · Journal of Virology · doi:10.1128/jvi.02223-14 · Cited by 36
Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles
McCullough, K. C., Milona, P., Thomann, L., Démoulins, T., Englezou, P. C., Suter, R., & Ruggli, N. (2014) · Vaccines · doi:10.3390/vaccines2040735 · Cited by 35
A Point Mutation in the Amino Terminus of TLR7 Abolishes Signaling without Affecting Ligand Binding
Iavarone, C., Ramsauer, K., Kubarenko, A. V., Debasitis, J. C., Leykin, I., Weber, A. N. R., Siggs, O. M., Beutler, B., Zhang, P., Otten, G. R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003585 · Cited by 33
Self-citation
A Glucocorticoid Reduces Adverse Effects of Adenovirus Vectors in the Cochlea
Ishimoto, S.-I., Kawamoto, K., Stöver, T., Kanzaki, S., Yamasoba, T., & Raphael, Y. (2003) · Audiology and Neurotology · doi:10.1159/000069000 · Cited by 31
Deviation from major codons in the Toll‐like receptor genes is associated with low Toll‐like receptor expression
Zhong, F., Cao, W., Chan, E., Tay, P. N., Cahya, F. F., Zhang, H., & Lu, J. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.02007.x · Cited by 26
Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice
Thoryk, E. A., Swaminathan, G., Meschino, S., Cox, K., Gindy, M. E., Casimiro, D. R., & Bett, A. J. (2016) · Vaccines · doi:10.3390/vaccines4040047 · Cited by 20
Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity
Maruggi, G., Shaw, C. A., Otten, G. R., Mason, P. W., & Beard, C. W. (2013) · Virology · doi:10.1016/j.virol.2013.07.021 · Cited by 14
Delivery of Tumor-Antigen-Encoding mRNA into Dendritic Cells for Vaccination
Michiels, A., Tuyaerts, S., Bonehill, A., Heirman, C., Corthals, J., & Thielemans, K. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-194-9_10 · Cited by 14
Lysosomotropic Agents Ameliorate Macrophage Dysfunction Following the Phagocytosis of IgG-Coated Erythrocytes: A Role for Lipid Peroxidation
Raley, M. J., Schwacha, M. G., & Loegering, D. J. (1997) · Inflammation · doi:10.1023/a:1027386206458 · Cited by 10
[The strategies of endosomal escape for intracellular gene delivery].
Wang, W., Dai, K., Hong, L., Cai, T., & Tang, L. (2014) · PubMed · Cited by 3
Untitled work
Hoerr, I. (2000) · doi:10.1002/1521-4141(200001)30:1

Research works printed but not linked: 5

Weissman D., 2015, Expert Vacc Rev
Vormehr M, 2015, J Immunol Res, 595363, 2015
Pepini T, 2017, Induction of an interferon-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design
Thoryk EA, 2016, Vaccines (Basel), 4
Wang WX, 2014, Yao Xue Xue Bao, 49, 1111

Sorted by citations

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 696
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 660
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584

See all 240

Authors: Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B.
Affiliations: GlaxoSmithKline (United States) (US)
Corresponding author: Iavarone, Carlo
ORCID: Yu, Dong
Venue: Expert Review of Vaccines
Publisher: Informa UK Limited
Published: 2017-07-28
Volume: 16
Issue: 9
Pages: 871-881
ISSN: 1476-0584 (ISSN-L)
1744-8395
DOI: 10.1080/14760584.2017.1355245
OpenAlex: W2736048901
Cited by: 234
References: 134
Citations by year: 2026: 13 · 2025: 29 · 2024: 34 · 2023: 33 · 2022: 35 · 2021: 45 · 2020: 26 · 2019: 13 · 2018: 5 · 2017: 1
FWCI: 1.27
Type: journal article
Language: en
Open access: closed
Locations: Expert Review of Vaccines (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: Defense Advanced Research Projects Agency
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: mRNA vaccines, vaccine mechanism of action, antigen localization, innate immunity, route of administration, mRNA delivery systems, vaccine design
MeSH terms: Humans, Immunity, Innate, RNA, Messenger, Vaccines, Drug Delivery Systems, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mechanism of action of mRNA-based vaccines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks